Provexis Plc

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00B0923P27
GBP
0.01
0 (6.78%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Provexis Plc stock-summary
stock-summary
Provexis Plc
Pharmaceuticals & Biotechnology
Provexis plc is engaged in developing and licensing the Fruitflow heart-health functional food ingredient for the global functional food sector. Fruitflow is a tomato extract, which inhibits platelet aggregation that causes heart attack, stroke and venous thrombosis. The syrup and powder versions of Fruitflow are used in foods, beverages and supplements. The powder version is used in a range of products, including soft gels, capsules, tablets and stick packs. The Company also offers Fruitflow + Omega-3 dietary supplement product, which is a two-in-one supplement in an easy to take capsule supporting healthy blood flow and normal heart function. Fruitflow + Omega-3 dietary supplement product is available through its e-commerce Website www.fruitflowplus.com. The Company's subsidiaries include Provexis Nutrition Limited, Provexis Natural Products Limited and Provexis (IBD) Limited, which are engaged in providing functional food, medical food and dietary supplement technologies.
Company Coordinates stock-summary
Company Details
2 Blagrave Street , READING None : RG1 1AZ
stock-summary
Tel: 44 1753 861777
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. C. Dawson Buck
Non-Executive Independent Chairman of the Board
Dr. Niamh O'Kennedy
Chief Scientific Officer, Executive Director
Ian Ford
Company Secretary, Executive Director
Mr. Frederic Boned
Non-Executive Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 14 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.55

stock-summary
Return on Equity

-34.89%

stock-summary
Price to Book

10.85